U.S. Markets closed

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

Atossa Genetics Inc. (ATOS)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.4884-0.0296 (-5.7143%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close0.5180
Bid0.4260 x 1000
Ask0.4500 x 3000
Day's Range0.4500 - 0.5377
52 Week Range0.3200 - 2.6000
Avg. Volume1,230,054
Market Cap5.71M
PE Ratio (TTM)-0.25
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research4 months ago

    ATOS: Balance Sheet Boosted by Recent Financing

    In early April 2017, Atossa closed a public offering with gross proceeds to Atossa of approximately $4.4 million. The offering included 664,000 Class A Units at a public offering price of $0.75 per Class A Unit, which consisted of 664,000 shares of Common Stock and Warrants to purchase 664,000 shares of Common Stock. The offering also included 3,502 Class B Units at a public offering price of $1,000 per Class B Unit, which consisted of 3,502 shares of Series A Convertible Preferred Stock convertible into a total of 4,669,333 shares of Common Stock and Warrants to purchase 4,669,333 shares of Common Stock.

  • American City Business Journals6 months ago

    Seattle breast cancer company stock plummets as it seeks funding to continue operations

    Atossa Genetics stock fell 27.5 percent after the company announced plans to raise $4.6 million in an underwritten public offering on Tuesday. The Seattle biotech company declined to comment during the stock offering period. Atossa develops drugs and medical devices that treat breast cancer and other breast conditions.

  • Zacks Small Cap Research6 months ago

    ATOS: Pure Player in the Breast Care Space

    On Jan 9, 2017, Atossa (ATOS) announced that it is transferring the site of its Phase II study of fulvestrant administered with its patented microcatheters in patients with ductal carcinoma in situ or breast cancer who are scheduled for lumpectomy or mastectomy. The study was initiated at Columbia University Medical Center Breast Cancer Programs (New York) and is now being transferred to Montefiore Medical Center in New York. This move comes about as the principal investigator, Dr. Sheldon M. Feldman, M.D., has relocated to Montefiore and is now Chief, Division of Breast Surgery & Breast Surgical Oncology, Director, Breast Cancer Services, and Professor, Department of Surgery, at the Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine, Montefiore Einstein Center for Cancer Care.